Drug · CHEMBL3545189
LANADELUMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LANADELUMAB. Drugs and targets, record CHEMBL3545189. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545189
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- DX-2930, Lanadelumab (shp643), Lanadelumab flyo, Lanadelumab-flyo, SHP-643, Tak-743
- ChEMBL
- Open Targets' highest stage
- Approval, for 1 of its 3 diseases, from ATC, EMA Human Drugs, FDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| KLKB1 | Plasma kallikrein | Plasma kallikrein inhibitor | INHIBITOR | https://conductscience.org/library/genes/3818 |
Source ChEMBL
Diseases3
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hereditary angioedema | Approval | ATC, EMA Human Drugs, FDA and TTD | 7 | 3 | https://conductscience.org/library/drugs?q=MONDO_0019623 |
| COVID-19 | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| injury | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0021178 |
Source Open Targets
Trials22
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04590586 | Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients | Phase 3 | 515 | 2022-06-29 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT02741596 | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | Phase 3 | 212 | 2020-05-11 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT03918239 | A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants. | Phase 1 | 190 | 2020-12-08 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | Phase 3 | 125 | 2018-04-24 | DX-2930 | Its name | ClinicalTrials.gov |
| NCT04206605 | A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) | Phase 3 | 77 | 2023-12-27 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT04444895 | A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor | Phase 3 | 73 | 2024-06-17 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT02093923 | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants | Phase 1 | 38 | 2016-08-01 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT03401671 | Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Phase 1 | 32 | 2019-07-29 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT05297786 | Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease | Phase 2 | 28 | 2026-01-20 | lanadelumab | Its name | ClinicalTrials.gov |
| NCT04070326 | A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children | Phase 3 | 21 | 2022-05-26 | lanadelumab | Its name | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rollover Participants vs Non-rollover Participants: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 105 of 109 | 101 of 103 | 212 | NCT02741596 | Trial comparisons |
| Rollover vs Non-Rollover: deaths from any cause | 0 of 109 | 0 of 103 | 212 | NCT02741596 | Trial comparisons |
| Rollover vs Non-Rollover: serious adverse events | 12 of 109 | 9 of 103 | 212 | NCT02741596 | Trial comparisons |
| SHP643 Prefilled Syringe (PFS) vs SHP643 Autoinjector (AI): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 19 of 94 | 30 of 96 | 190 | NCT03918239 | Trial comparisons |
| SHP643 Prefilled Syringe (PFS) vs SHP643 Autoinjector (AI): deaths from any cause | 0 of 94 | 0 of 96 | 190 | NCT03918239 | Trial comparisons |
| SHP643 Prefilled Syringe (PFS) vs SHP643 Autoinjector (AI): serious adverse events | 2 of 94 | 2 of 96 | 190 | NCT03918239 | Trial comparisons |
| Lanadelumab 300 mg vs Placebo: Number of Participants Achieving Attack-Free Status During the Treatment Period of Day 0 Through Day 182 | 2 of 50 | 1 of 27 | 77 | NCT04206605 | Trial comparisons |
| Lanadelumab 300 mg vs Placebo: deaths from any cause | 0 of 50 | 0 of 27 | 77 | NCT04206605 | Trial comparisons |
| Lanadelumab 300 mg vs Placebo: serious adverse events | 7 of 50 | 1 of 27 | 77 | NCT04206605 | Trial comparisons |
| Lanadelumab 300 mg vs Placebo: Number of Participants Achieving Attack-Free Status During the Presumed Steady State Period of Day 70 Through Day 182 | 3 of 49 | 4 of 27 | 76 | NCT04206605 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials13
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 24980392 | RESULT | 1 | PubMed |
| 42928084 | DERIVED | 1 | PubMed |
| 40469312 | DERIVED | 2 | PubMed |
| 39128590 | DERIVED | 1 | PubMed |
| 37730089 | DERIVED | 1 | PubMed |
| 37028510 | DERIVED | 2 | PubMed |
| 36326435 | DERIVED | 1 | PubMed |
| 36153561 | DERIVED | 2 | PubMed |
| 34473343 | DERIVED | 1 | PubMed |
| 34287942 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3545189
GET https://conductscience.org/api/drugs/v1/CHEMBL3545189/trials?page=2